Heart attack patients

The liver, known as the chemical reactor of the body, serves to eliminate drugs and other compounds from the body. In one such process, lidocaine (a drag given to heart attack patients) may be converted either into MEGX by deethylation, or into hydroxylidocaine (OHLDD) by hydroxylation. Assuming that the liver may be represented by a CSTR, determine the... 

Beta-blocker drugs that reduce the force of the heart s pumping and lower blood pressure markedly reduce the chance of death among heart attack patients. 

Tissue plasminogen activator (TPA) activates plasmin, an enzyme involved in dissolving clots effective in treating heart attack patients. 

COR Therapeutics, Schering-Plough and Genentech announce plans to study ENTEGREL1N eptifibatide, injection in combination with TNKase-tenecteplase, in heart attack patients. 

Aspirin is inducted into the Natural Museum of American History at the Smithsonian Institute for its century of reducing pains, aches, fevers, and inflammation, and for saving the lives of thousands of heart attack patients. 

Italian doctors in the GISSI-Prevention Study had the same happy results when heart attack patients tried the Mediterranean diet, this time supplemented with omega-3 fatty acids. After three and a half years, the rates of nonfatal heart attacks, strokes, and deaths were down substantially. 

Many cancer myths persist, exaggerating its worst aspects. Although cancer is reputed to be a hopeless condition, nearly half of all cancer patients can expect to be alive and free of any sign of the disease in 5 years, a much better outlook than that facing most heart attack patients. 

The concentration of t-PA in human blood is 2—5 ng/mL, ie, 2—5 ppb. Plasminogen activation is accelerated in the presence of a clot, but the rate is slow. The dissolution of a clot requites a week or more during normal repair of vascular damage (17). Prevention of irreversible tissue damage during a heart attack requires that a clot, formed by mpture of an atherosclerotic plaque, be dissolved in a matter of hours. This rapid thrombolysis (dissolution of the clot) must be achieved without significant tibrinogenolysis elsewhere in the patient. 

Ca.rdia.c-AssistDevices. The principal cardiac-assist device, the intra-aortic balloon pump (lABP), is used primarily to support patients before or after open-heart surgery, or patients who go into cardiogenic shock. As of the mid-1990s, the lABP was being used more often to stabilize heart attack victims, especially in community hospitals which do not provide open-heart surgery. The procedure consists of a balloon catheter inserted into the aorta which expands and contracts to assist blood flow into the circulatory system and to reduce the heart s workload by about 20%. The disposable balloon is powered by an external pump console. 

Other Cardiovascular Agents Effecting Atherosclerosis. A large amount of clinical data is available concerning semm Upid profiles in patients subjected to dmg therapy for other cardiovascular diseases. Atheroma, for example, may be the underlying cause of hypertension and myocardial infarction. There are on the order of 1.5 million heart attacks pet year in the United States (155). 

These drugp are contraindicated in patients with known hypersensitivity to the drug or to any constituents of the drug, after a recent myocardial infarction (heart attack), or in patients with thyrotoxicosis. When hypothyroidism is a cause or contributing factor to a myocardial infarction or heart disease, the physician may prescribe small doses of thyroid hormone... 

A patient who recently recovered from a minor heart attack is suffering from periods of ectopic ventricular beats, originating from what is believed to be a small area of post-ischaemic fibrosis in the free wall of the left ventricle. 

Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs. diuretic The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002 288(23) =2981-2997. 

Event/Censor A binomial outcome such as "success/failure," "death/life," "heart attack/no heart attack." If the event happened to the subject, then the event variable is set to 1. If it is certain that the patient did not experience the event, then the event variable is set to 0. Otherwise, this variable should be missing. 

Because ketones are passed out of the body in the urine, a doctor can detect the onset of diabetic acidosis by doing a urine test. If ketones are present in the urine, it is a signal to the doctor that the patients diabetes is out of control. Without treatment, the patient could get very sick. On rare occasions, even Type I or Type II diabetics who take their medication can develop acidosis, usually as a result of some other serious health issue such as an infection or a heart attack. 

The difference in opiate pharmacology between people with and without pain also applies to addiction. The drug-seeking behaviour synonymous with drug addiction does not occur in patients given opiates for pain relief in childbirth, operations or heart attacks (Porter and Jick, 1980). Clearly, drug addicts are not in pain, and it has consequently been argued that medical use of opiates does not produce addicts (McQuay, 2001). 

Anticoagulants are substances that can prevent blood from clotting and, hence, are of therapeutic use in cases where a high risk of coagulation is diagnosed. They are often administered to patients with coronary heart disease and to patients who have experienced a heart attack or... 

The FDA approved this selective cyclooxigenase (COX)-2 inhibitor (Vioxx) for the treatment of pain and inflammation in 1999. This NSAID demonstrated to have a lower risk of side effects such as gastrointestinal ulcers and bleeding than nonse-lective COX inhibitors, for example, ibuprofen. In 2004, a long-term study of Vioxx in patients at increased risk of colon polyps was halted because of an increased cardiovascular risk (heart attack, stroke) in the rofecoxib group. Subsequently, Merck withdrew the drug from the world market at the end of September 2004 [46]. 

---